Drug Database
Back to search

Belgium· BE-AMP-SAM579164-00

Xofluza 40 mg

A baloxavir marboxil product containing baloxavir marboxil, registered in Belgium by Roche Registration. The same ATC class is registered in 13 of our 19 countries.

ATC J05AX25

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedXofluza 40 mgATCJ05AX25REGISTER NO.BE-AMP-SAM579164-00PACKS LISTED1CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about baloxavir marboxilAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Baloxavir marboxil is registered in 13 of 19 countries.

Countries holding a registration under ATC J05AX25 (baloxavir marboxil), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 8 of them publish a price we can compare per daily dose
Search baloxavir marboxil products by name

Baloxavir marboxil · ATC J05AX25

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Baloxavir Marboxil
Manufacturer
Roche Registration
Country
Belgium (BE)
ATC code
J05AX25
ATC class
Baloxavir marboxil
Defined daily dose
40 mg, O
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 1

  • be_apb
    4307591

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

40 interactions on record for baloxavir marboxil.

Graded by severity as the source publishes them — 40 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check baloxavir marboxil against other medicinesHow interaction checks work

Baloxavir marboxil · interactions on record

40 records

  • 40 moderate

Most severe, free to view

  • Magnesium carbonateA02AA01moderate
  • Magnesium oxideA02AA02moderate
  • Magnesium hydroxideA02AA04moderate
  • Kombinationen von AluminiumsalzenA02AB10moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Baloxavir marboxil in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All baloxavir marboxil products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Xofluza
  • Liechtenstein · Xofluza
  • Norway · Xofluza

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/71ff9ee3-80f6-43c3-8921-44461db729b4
GET /v1/drugs/71ff9ee3-80f6-43c3-8921-44461db729b4?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Film-coated tablet",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Xofluza 40 mg",
  "name_fr": "Xofluza 40 mg",
  "name_nl": "Xofluza 40 mg",
  "amp_code": "SAM579164-00",
  "strengths": [
    "40.0000",
    "40.0000",
    "155.8000"
  ],
  "pack_count": 2,
  "substances": [
    "Baloxavir Marboxil",
    "Lactose Monohydrate",
    "Sodium Stearyl Fumarate"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Baloxavir Marboxil",
  "authorisation_numbers": [
    "EU/1/20/1500/002",
    "EU/1/20/1500/004"
  ]
}
API referenceMCP serverPlans

See everything about baloxavir marboxil.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console